Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Other, SGLT2i Feb 10 | 2023Novo Nordisk and Heartseed Dose First Patient in Ph1/2 LAPiS Trial of HS-001; Finerenone Receives EU Approval for FIGARO-DKD Label ExtensionPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Feb 09 | 2023AZ Q4 ’22 Earnings; Oramed to Consider M&A OpportunitiesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 08 | 2023Vertex Q4 ’22 Earnings; Dario Partners with DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Feb 07 | 2023Dexcom G7 Super Bowl DTC; Medtronic Initiates 780G+DS5 GCM Trial; Forxiga Receives EU Approval for Chronic HF; Merck Initiates Vericiguat Pediatric HF TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 03 | 2023Sanofi and Regeneron Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, SGLT2i Feb 02 | 2023Lilly, Merck, and Roche Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Feb 01 | 2023Amgen, Novartis, and Lannett Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal Feb 01 | 2023Novo Nordisk Q4 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 31 | 2023Pfizer Q4 ’22 Earnings; Lilly Initiates Open-Label SURPASS-SWITCH-2 Study; Fractyl Health Announces Positive Week 24 REVITA-T2Di Data; Sciwind Initiates Dosing for Ph3 Ecnoglutide Trials in China; Lifescan Announces Publication of Connected BGM RWEPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 27 | 2023Viatris’s Generic Dapagliflozin and Lilly’s Trulicity Pediatric Extension Receive Positive CHMP opinions; Medtronic’s Wearable Partner Files for Bankruptcy; Nemaura Looks to Raise Additional CapitalPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 26 | 2023Diabetes Research Institute Appoints Matthias von Herrath as Scientific Director; Nemaura Receives First proBEAT Purchase Order from HealthFleetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 25 | 2023Abbott Q4 ’22 Earnings; Tidepool Loop Receives FDA Clearance; Lilly to Expand Incretin Manufacturing Capacity; Novo Receives Marketing Practices Complaint; AGC Biologics to Manufacture Tzield; Nemaura Reports Positive Miboko Data; J&J Q4 ’22 Earnings; and Embecta Opens New HeadquartersPurchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Jan 23 | 2023Another Branded SGLT2i Approved by FDA; Tandem Completes AMF Medical Acquisition; January CHMP AgendaPurchase Blast
$599
Posted in: SGLT2i Jan 20 | 2023Jardiance CKD sNDA Accepted by FDA Without Priority ReviewPurchase Blast
$599
Posted in: Other Jan 19 | 2023FDA Accepts OCA NASH NDA; Palatin Initiates Ph2b DKD TrialPurchase Blast
$599
Posted in: DPP-IVi, Other Jan 18 | 2023Diamyd Initiates Ph2 Trial in At-risk Individuals; Teladoc Cuts 300 Jobs; Merck to Resolve Sitagliptin Contamination IssuePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 13 | 2023Rybelsus Approved as First-Line Therapy for T2DM; Biocon Receives Another CRL; Tandem Initiates Control-IQ 2.0 Feasibility Study in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jan 12 | 2023JPM 2023 Day 4: TNDM, ICPT, LXRX, MNKD, and XERS; Oramed Discontinues Ph3 Development ORMD-0801 in T2DM; Versanis Initiates Ph2b Obesity Trial EnrollmentPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
